Cohen Capital Management Inc. increased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,096 shares of the medical research company’s stock after acquiring an additional 102 shares during the quarter. Cohen Capital Management Inc.’s holdings in Amgen were worth $596,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen during the fourth quarter valued at about $29,000. United Community Bank bought a new stake in shares of Amgen during the fourth quarter valued at about $29,000. Horizon Financial Services LLC bought a new stake in shares of Amgen during the first quarter valued at about $28,000. Planned Solutions Inc. purchased a new position in shares of Amgen during the fourth quarter worth about $30,000. Finally, Delos Wealth Advisors LLC grew its holdings in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Trading Up 1.1 %
Shares of NASDAQ:AMGN traded up $3.42 during trading on Thursday, reaching $325.09. 2,253,879 shares of the company traded hands, compared to its average volume of 2,721,015. The firm has a market capitalization of $174.39 billion, a price-to-earnings ratio of 46.44, a P/E/G ratio of 2.81 and a beta of 0.58. Amgen Inc. has a 52-week low of $224.09 and a 52-week high of $329.72. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The business’s fifty day moving average is $308.79 and its 200-day moving average is $294.36.
Insider Activity at Amgen
In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.69% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
AMGN has been the subject of several recent analyst reports. Royal Bank of Canada boosted their price objective on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Raymond James initiated coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. Barclays raised Amgen from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Finally, BMO Capital Markets boosted their price objective on Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.00.
Read Our Latest Stock Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- What is Insider Trading? What You Can Learn from Insider Trading
- Sales Breakout Sends This Semiconductor Stock to Record High
- 3 Small Caps With Big Return Potential
- Surprise Buying Opportunity on This Dividend Aristocrat
- How to Capture the Benefits of Dividend Increases
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.